NCT04627428View on ClinicalTrials.gov

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Dry Age-related Macular Degeneration
Interventions
BIOLOGICAL

RPESC-RPE-4W

RPESC-RPE-4W

Trial Locations (3)

48105

RECRUITING

University of Michigan Kellogg Eye Center, Ann Arbor

90211

RECRUITING

Retina Vitreous Associates Medical Group, Beverly Hills

94303

RECRUITING

Spencer Center for Vision Research, Palo Alto

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Eye Institute (NEI)

NIH

collaborator

Regenerative Research Foundation

UNKNOWN

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Luxa Biotechnology, LLC

INDUSTRY

NCT04627428 - Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter